AHA 2023 Data Highlights Potential of Acoramidis in ATTR-CM
Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.
Source: hcplive.com
Page 3 - Win Ratio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Win Ratio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Win Ratio Today - Breaking & Trending Today
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of...
Source: marketscreener.com
BridgeBio Pharma Presents Additional Clinical Outcomes Data
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related...
Source: globenewswire.com
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study ...
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant
Source: bdtonline.com
Interpreting New IV Iron Guidelines, with Muthiah Vaduganathan, MD, MPH
On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.
Source: hcplive.com